Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma 1Endometrial Neoplasms 1

Interventions

Paclitaxel 108Carboplatin 97pembrolizumab 64Cisplatin 63Cyclophosphamide 45Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 25olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × TAS-116 × Gynecologic × Clear all
NCT05655598 2024-09-19

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Brown University

Phase 1 Withdrawn
GenitourinaryGynecologicSarcoma

Urinary Bladder Neoplasms, Sarcoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡